A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus

Background  In a recent open pilot trial, R‐salbutamol sulphate, a well‐known molecule with anti‐inflammatory effects, was tested successfully on patients with therapy‐resistant discoid lupus erythematosus (DLE).

[1]  A. Troxel,et al.  The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. , 2008, Archives of dermatology.

[2]  M. Sticherling,et al.  Diagnostic approach and treatment of cutaneous lupus erythematosus , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[3]  B. Prenner.  Role of long-acting β2-adrenergic agonists in asthma management based on updated asthma guidelines , 2008, Current opinion in pulmonary medicine.

[4]  H. Wulf,et al.  Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. , 2007, Archives of dermatology.

[5]  H. Wulf,et al.  Assessment of atopic eczema: clinical scoring and noninvasive measurements , 2007, The British journal of dermatology.

[6]  Lars Thomassen,et al.  Instrumental assessment of atopic eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema. , 2006, Journal of the American Academy of Dermatology.

[7]  J. Berlin,et al.  The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. , 2005, The Journal of investigative dermatology.

[8]  J. Callen.  Management of "refractory" skin disease in patients with lupus erythematosus. , 2005, Best practice & research. Clinical rheumatology.

[9]  H. Kita,et al.  Effects of (R)‐ and (S)‐isomers of β‐adrenergic agonists on eosinophil response to interleukin‐5 , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  L. Borish,et al.  Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. , 2002, The Journal of allergy and clinical immunology.

[11]  G. Burmester,et al.  Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases , 2001, Annals of the rheumatic diseases.

[12]  R. Jacobs,et al.  Patients with Systemic Lupus Erythematosus Differ from Healthy Controls in Their Immunological Response to Acute Psychological Stress , 1999, Brain, Behavior, and Immunity.

[13]  H. Wulf,et al.  The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis. , 1997, Acta Dermato-Venereologica.

[14]  R. Naclerio,et al.  Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. , 1997, Pulmonary pharmacology & therapeutics.

[15]  P. von Wichert,et al.  Beta 2-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatic diseases. , 1992, European journal of clinical investigation.

[16]  J. Callen.  Therapy of cutaneous lupus erythematosus , 1982, The Medical clinics of North America.

[17]  A. Kuhn,et al.  Cutaneous lupus erythematosus: molecular and cellular basis of clinical findings. , 2008, Current directions in autoimmunity.

[18]  S. Peters,et al.  beta-Agonist enhances type 2 T-cell survival and accumulation. , 2007, The Journal of allergy and clinical immunology.

[19]  G. Raugi,et al.  Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus. , 2004, Advances in Dermatology.

[20]  W. J. Morginson.  [Lupus erythematosus]. , 1960, Revista medica hondurena.